Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 1
2021 1
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer.
Agostini A, Guerriero I, Piro G, Quero G, Roberto L, Esposito A, Caggiano A, Priori L, Scaglione G, De Sanctis F, Sistigu A, Musella M, Larghi A, Rizzatti G, Lucchetti D, Alfieri S, Sgambato A, Bria E, Bizzozero L, Arena S, Ugel S, Corbo V, Tortora G, Carbone C. Agostini A, et al. Among authors: esposito a. J Transl Med. 2023 Nov 23;21(1):843. doi: 10.1186/s12967-023-04733-z. J Transl Med. 2023. PMID: 37996891 Free PMC article.
Identification of spatially-resolved markers of malignant transformation in Intraductal Papillary Mucinous Neoplasms.
Agostini A, Piro G, Inzani F, Quero G, Esposito A, Caggiano A, Priori L, Larghi A, Alfieri S, Casolino R, Scaglione G, Tondolo V, Cammarota G, Ianiro G, Corbo V, Biankin AV, Tortora G, Carbone C. Agostini A, et al. Among authors: esposito a. Nat Commun. 2024 Mar 29;15(1):2764. doi: 10.1038/s41467-024-46994-2. Nat Commun. 2024. PMID: 38553466 Free PMC article.
Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms of Treatment Response.
Piro G, Agostini A, Larghi A, Quero G, Carbone C, Esposito A, Rizzatti G, Attili F, Alfieri S, Costamagna G, Tortora G. Piro G, et al. Among authors: esposito a. Front Med (Lausanne). 2021 Dec 23;8:793144. doi: 10.3389/fmed.2021.793144. eCollection 2021. Front Med (Lausanne). 2021. PMID: 35004765 Free PMC article. Review.
CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer.
Piro G, Carbone C, Agostini A, Esposito A, De Pizzol M, Novelli R, Allegretti M, Aramini A, Caggiano A, Granitto A, De Sanctis F, Ugel S, Corbo V, Martini M, Lawlor RT, Scarpa A, Tortora G. Piro G, et al. Among authors: esposito a. Br J Cancer. 2023 Jan;128(2):331-341. doi: 10.1038/s41416-022-02028-6. Epub 2022 Nov 16. Br J Cancer. 2023. PMID: 36385556 Free PMC article.